Rennert, US
Casey Clarence Rennert, Manitowoc, WI US
Patent application number | Description | Published |
---|---|---|
20130133636 | Portable and Adjustable Clay Target Launching Apparatus - A portable and adjustable clay target launching apparatus for use with a clay pigeon launcher includes a framework. A tilt adjustment assembly is coupled to the framework, and includes a shaft and a tilt assembly input member operatively coupled to the shaft such that the shaft is rotated by operation of the tilt assembly input member. A base member is configured to secure the clay pigeon launching device, the base member being operatively coupled to the shaft and configured to tilt side to side when the shaft is rotated by operation of the tilt assembly input member. A rotational adjustment assembly operatively couples the base member to the tilt adjustment assembly, the rotational adjustment assembly being movable between a released configuration at which the base member is selectively rotatable about a sprocket and a locked configuration at which the base member is not rotatable. | 05-30-2013 |
Gerald Rennert, Phoenix, AZ US
Patent application number | Description | Published |
---|---|---|
20100031900 | LOW COST TANKLESS PORTABLE WATER HEATER - A portable tankless water heater includes a heat exchanger disposed in a sealed housing with an inlet cold water line and an outlet hot water line extending outside the sealed housing. A burner, disposed in an operative relationship with said heat exchanger is provided for heating water flowing through said heat exchanger and an exhaust system induces draft of air from a housing air inlet through said heat exchanger and out of a housing flue outlet. | 02-11-2010 |
Owen M. Rennert, Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20080255000 | Method Evolved for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd) - Methods for predicting an individual's genetic risk for developing ARMD is disclosed, as are arrays and kits which can be used to practice the method. The method includes screening for mutations and/or polymorphisms in ARMD-associated molecules, such as CFH, LOC387715, BF, C2, ABCR, Fibulin 5, VMD2, TLR4, CX3CR1, CST3, MnSOD, MEHE, paraoxonase, APOE, ELOVL4 and hemicentin-1. | 10-16-2008 |
20090054256 | METHOD EVOLVED FOR RECOGNITION OF THROMBOPHILIA (MERT) - Methods for predicting an individual's genetic risk for developing venous thrombosis in diverse ethnic populations is disclosed, as are arrays and kits which can be used to practice the method. The method includes screening for mutations, polymorphisms, or both, in at least eight venous thrombosis-related molecules, such as antithrombin III, protein C, protein S, fibrinogen, factor V, prothrombin (factor II), methylenetetrahydrofolate reductase (MTHFR), and angiotensin I-converting enzyme (ACE) molecules which are associated with venous thrombosis. | 02-26-2009 |
Paul Rennert, Holliston, MA US
Patent application number | Description | Published |
---|---|---|
20100150905 | KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS - Compositions and methods for treating Th2- and ThI-mediated disease are provided. | 06-17-2010 |
20130089539 | KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS - Compositions and methods for treating Th2- and Th1-mediated disease are provided. | 04-11-2013 |
Paul Rennert, Millis, MA US
Patent application number | Description | Published |
---|---|---|
20100061985 | ANTAGONISTS OF TWEAK AND OF TWEAK RECEPTOR AND THEIR USE TO TREAT IMMUNOLOGICAL DISORDERS - The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders. | 03-11-2010 |
20120027751 | ANTAGONISTS OF TWEAK AND OF TWEAK RECEPTOR AND THEIR USE TO TREAT IMMUNOLOGICAL DISORDERS - The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders. | 02-02-2012 |
20120189634 | TACI AS AN ANTI-TUMOR AGENT - A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the TACI reagent. | 07-26-2012 |
20150218247 | TACI AS AN ANTI-TUMOR AGENT - A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the TACI reagent. | 08-06-2015 |
Paul D. Rennert, Millis, MA US
Patent application number | Description | Published |
---|---|---|
20120156214 | SOLUBLE LYMPHOTOXIN-BETA RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES - Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses. | 06-21-2012 |
Paul D. Rennert, Holliston, MA US
Patent application number | Description | Published |
---|---|---|
20080219967 | Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases - Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses. | 09-11-2008 |
20090155836 | METHODS FOR TREATING HIV INFECTED SUBJECTS - Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis. | 06-18-2009 |
20100080798 | KIM-1 ANTAGONISTS AND USE TO MODULATE IMMUNE SYSTEM - The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-γ by lymphocytes or other immune cells in a mammal. Inhibition of IFN-γ is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease. | 04-01-2010 |
20150110792 | ANTI-TIM-1 Antibodies And Uses Thereof - Antibodies and antibody fragments that bind to human TIM-1 on the BED face of the protein are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit or reduce TIM-1 binding to phosphatidylserine, inhibit or reduce TIM-1 binding to dendritic cells, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions. | 04-23-2015 |
Robert C. Rennert, Palo Alto, CA US
Patent application number | Description | Published |
---|---|---|
20160102288 | EFFICIENT STEM CELL DELIVERY INTO BIOMATERIALS USING CAPILLARY DRIVEN ENCAPSULATION - Efficient stem cell delivery into biomaterials using capillary driven encapsulation are disclosed herein where stem/progenitor and/or tissue specific cells are rapidly and efficiently seeded via capillary driven encapsulation into a porous scaffold for cell deliver in the skin or any other organ. The rapid capillary force approach maximizes both seeding time and efficiency by combining hydrophobic, entropic and capillary forces to promote active, ‘bottom-up’ cell engraftment. This methodology uses micro domain patterned biopolymers in a porous dry gel to generate capillary pressure to move a viscous stem cell mix from a hydrophobic reservoir into the polymer matrix to promote active cell seeding within the entire gel volume. | 04-14-2016 |